|
|
Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma
Basic Trial Information Trial Description Summary Eligibility Criteria Trial Contact Information
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
MCC-13224 NCT00323206
|
|
|
Trial Description
Summary The purpose of this research study is to study a type of gene therapy treatment called plasmid electroporation. This type of treatment involves the injection of a gene into some melanoma tumors located near the surface of the skin, followed by a burst of electricity into the tumor to cause the tumor to take up the gene. This study is a Phase I study to determine the side effects and the correct dose of this type of treatment and also its effectiveness in treating melanoma. While the electroporation technique has been used in people, the combination of plasmid injection and electroporation is being tried in human beings for the first time. Eligibility Criteria Inclusion Criteria: - Patients must have cytologically/histologically documented metastatic malignant melanoma with lesions near the skin that would be accessible to electroporation and Fine Needle Aspiration (FNA) and biopsy.
- Patients must have ECOG performance status 0-2
- Patients may have had prior chemotherapy or immunotherapy (with vaccines or Interferon or IL-2) with progression or persistent disease. All chemotherapy or immunotherapy must be stopped for 4 weeks prior to electroporation. Patients may have had radiation therapy, but must have progressive disease after radiation therapy if the lesions to be electroporated are within the radiation field. In addition, it must be at least 2 weeks since administration of radiation therapy and all signs of toxicity must have abated.
- Patients must be able to give informed consent and able to follow guidelines given in the study
- Patients must have a minimum of two eligible tumors and may have up to four eligible tumors treated with electroporation.
Exclusion Criteria: - Patients may not have had prior therapy with IL-12 or prior genetic therapy
- Patients must not have evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess, etc.) at time of study entry.
- Patients must have adequate renal and normal hepatic function (creatinine < 1.5 x upper limit of normal (ULN), bilirubin and SGOT (AST) within institutional normal limits) obtained within 4 weeks prior to registration.
- Patients must have absolute neutrophil count (ANC) > 1500/mm3 and platelet count > 100,000 /mm3 within 4 weeks prior to registration.
- Pregnant and breast feeding women are excluded from the study because effects on the fetus are unknown and there may be a risk of increased fetal wastage.
- Women of childbearing age must have a negative pregnancy test and be willing to use a highly effective method of contraception. Men who are sexually active must also be willing to use an accepted and effective method of contraception.
- Patients with electronic pacemakers or defibrillators are excluded from this study as the effect of electroporation on these devices is unknown. Patients with significant cardiac arrhythmia’s (including ventricular tachycardia, ventricular fibrillation or WPW syndrome) are also excluded.
- Patients with a history of epilepsy are excluded unless they have been seizure free over the last 5 years and are thought to be at low risk for seizure by their neurologist.
- Tumors that invade the bone, major blood vessels or nerves are ineligible because those tumors are contraindications to the use of electroporation.
Trial Contact Information
Trial Lead Organizations/Sponsors H. Lee Moffitt Cancer Center and Research Institute at University of South Florida Indiana University Melvin and Bren Simon Cancer Center
Adil Daud | | Principal Investigator |
Trial Sites
|
|
|
|
U.S.A. |
|
Florida |
|
|
Tampa |
|
| | | | | | | | H. Lee Moffitt Cancer Center and Research Institute at University of South Florida |
| | Adil Daud, MD |
Ph: 813-745-8581 |
| | Patricia Urbas, RN |
Ph: 813-745-8352 |
|
Email:
urbaspa@moffitt.usf.edu |
| | Adil Daud | Principal Investigator |
| | Ronald C. DeConti | Sub-Investigator |
| | Vernon K. Sondak | Sub-Investigator |
| | Christopher Puleo, PA | Sub-Investigator |
| | Stephanie Andrews, ARNP | Sub-Investigator |
|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00323206 Information obtained from ClinicalTrials.gov on May 27, 2008 Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov. Back to Top |
|